Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Galmed PharmaceuticalsAerpio PharmaceuticalsNeuroBo PharmaceuticalsMonopar TherapeuticsVaccinex
SymbolNASDAQ:GLMDNASDAQ:ARPONASDAQ:NRBONASDAQ:MNPRNASDAQ:VCNX
Price Information
Current Price$3.17$1.11$3.12$5.73$2.33
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.51.21.71.51.5
Analysis Score3.43.33.53.53.3
Community Score3.32.53.33.12.1
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.80.81.7
Earnings & Valuation Score0.60.00.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$18.14$2.75$16.00$30.00$7.00
% Upside from Price Target472.33% upside147.75% upside412.82% upside423.56% upside200.43% upside
Trade Information
Market Cap$79.52 million$52.52 million$61.37 million$72.01 million$66.27 million
Beta2.32.020.69N/A1.86
Average Volume375,8952,080,786406,988256,0864,834,721
Sales & Book Value
Annual Revenue$2.04 million$20.16 millionN/AN/A$520,000.00
Price / Sales38.982.61N/AN/A127.44
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$3.30 per share$0.90 per share$0.79 per share$1.19 per share($0.15) per share
Price / Book0.961.23N/AN/A-15.53
Profitability
Net Income$-20,460,000.00$-23,270,000.00$-21,310,000.00$-4,220,000.00$-31,860,000.00
EPS($0.97)($0.53)($4.08)($0.45)($2.47)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-43.28%-8.19%-224.41%-42.84%N/A
Return on Assets (ROA)-39.33%-7.63%-171.64%-40.98%-367.05%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.30%
Current Ratio9.81%19.74%3.57%29.65%1.32%
Quick Ratio9.81%19.74%3.57%29.65%1.32%
Ownership Information
Institutional Ownership Percentage31.53%34.53%4.50%0.66%2.09%
Insider Ownership PercentageN/A31.10%56.10%48.40%68.60%
Miscellaneous
Employees171212639
Shares Outstanding25.08 million47.31 million19.67 million12.57 million28.44 million
Next Earnings Date5/13/2021 (Estimated)5/6/2021 (Estimated)5/19/2021 (Estimated)5/6/2021 (Estimated)5/13/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Zacks: Brokerages Anticipate Vaccinex, Inc. (NASDAQ:VCNX) to Post -$0.39 EPSZacks: Brokerages Anticipate Vaccinex, Inc. (NASDAQ:VCNX) to Post -$0.39 EPS
americanbankingnews.com - April 13 at 2:12 AM
Vaccinex, Inc. (NASDAQ:VCNX) Short Interest UpdateVaccinex, Inc. (NASDAQ:VCNX) Short Interest Update
americanbankingnews.com - March 29 at 9:50 AM
The Huntington’s pipeline takes a blow - VantageThe Huntington’s pipeline takes a blow - Vantage
evaluate.com - March 23 at 6:43 PM
Form 8-K VACCINEX, INC. For: Mar 16 - StreetInsider.comForm 8-K VACCINEX, INC. For: Mar 16 - StreetInsider.com
streetinsider.com - March 16 at 7:17 PM
Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update - GlobeNewswireVaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update - GlobeNewswire
globenewswire.com - March 16 at 9:16 AM
Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate UpdateVaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - March 16 at 9:16 AM
Vaccinex - Consensus Indicates Potential 370.4% Upside - DirectorsTalk InterviewsVaccinex - Consensus Indicates Potential 370.4% Upside - DirectorsTalk Interviews
directorstalkinterviews.com - March 11 at 1:12 AM
Vaccinex Inc (VCNX) Up 7.54% in Premarket Trading - InvestorsObserverVaccinex Inc (VCNX) Up 7.54% in Premarket Trading - InvestorsObserver
investorsobserver.com - March 10 at 8:12 PM
What is Going on With Vaccinex, Inc. (VCNX)? - Park TelegraphWhat is Going on With Vaccinex, Inc. (VCNX)? - Park Telegraph
parktelegraph.com - March 9 at 12:27 PM
Vaccinex - Consensus Indicates Potential 286.8% Upside - DirectorsTalk InterviewsVaccinex - Consensus Indicates Potential 286.8% Upside - DirectorsTalk Interviews
directorstalkinterviews.com - March 4 at 4:11 PM
Vaccinex: Still Gets An Incomplete Grading - Seeking AlphaVaccinex: Still Gets An 'Incomplete' Grading - Seeking Alpha
seekingalpha.com - March 1 at 5:47 PM
4 Hot Penny Stocks Bouncing After Recent Market Sell-Off - Penny Stocks4 Hot Penny Stocks Bouncing After Recent Market Sell-Off - Penny Stocks
pennystocks.com - February 24 at 6:55 PM
Vaccinex - Consensus Indicates Potential 164.2% Upside - DirectorsTalk InterviewsVaccinex - Consensus Indicates Potential 164.2% Upside - DirectorsTalk Interviews
directorstalkinterviews.com - February 24 at 12:51 PM
Should Biotechnology Stock Vaccinex Inc (VCNX) Be in Your Portfolio Wednesday? - InvestorsObserverShould Biotechnology Stock Vaccinex Inc (VCNX) Be in Your Portfolio Wednesday? - InvestorsObserver
investorsobserver.com - February 24 at 12:51 PM
AREV Nanotec Board of Directors Welcomes Kevin Phelps - StreetInsider.comAREV Nanotec Board of Directors Welcomes Kevin Phelps - StreetInsider.com
streetinsider.com - February 24 at 7:51 AM
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts - Yahoo FinanceThe Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts - Yahoo Finance
finance.yahoo.com - February 23 at 10:59 PM
Tuesday Sector Laggards: Biotechnology, Drugs - NasdaqTuesday Sector Laggards: Biotechnology, Drugs - Nasdaq
nasdaq.com - February 23 at 12:54 PM
Extensive Demand for T-Cell Adoptive Immunotherapy Rising with Growing Prevalence of Cancer - StreetInsider.comExtensive Demand for T-Cell Adoptive Immunotherapy Rising with Growing Prevalence of Cancer - StreetInsider.com
streetinsider.com - February 23 at 12:54 PM
Premarket Mover: Vaccinex Inc (VCNX) Down 11.94% - InvestorsObserverPremarket Mover: Vaccinex Inc (VCNX) Down 11.94% - InvestorsObserver
investorsobserver.com - February 23 at 12:54 PM
Should You Buy Vaccinex Inc (VCNX) Stock Monday? - InvestorsObserverShould You Buy Vaccinex Inc (VCNX) Stock Monday? - InvestorsObserver
investorsobserver.com - February 22 at 8:14 PM
Vaccinex announces licensing deal with Surface Oncology - Seeking AlphaVaccinex announces licensing deal with Surface Oncology - Seeking Alpha
seekingalpha.com - February 22 at 8:14 PM
VCNX Stock Price Increased Over 18% Intraday: Why It HappenedVCNX Stock Price Increased Over 18% Intraday: Why It Happened
pulse2.com - February 22 at 3:13 PM
Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology - GlobeNewswireVaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology - GlobeNewswire
globenewswire.com - February 22 at 10:12 AM
Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface OncologyVaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology
finance.yahoo.com - February 22 at 10:12 AM
VCNX Stock: 11 Things to Know About Vaccinex and the Deals That Have Shares Soaring - NasdaqVCNX Stock: 11 Things to Know About Vaccinex and the Deals That Have Shares Soaring - Nasdaq
nasdaq.com - February 21 at 12:24 PM
DateCompanyBrokerageAction
3/25/2021Galmed PharmaceuticalsHC WainwrightLower Price Target
1/8/2021Galmed PharmaceuticalsRaymond JamesLower Price Target
11/25/2020Galmed PharmaceuticalsCanaccord GenuityLower Price Target
11/13/2020Galmed PharmaceuticalsCantor FitzgeraldReiterated Rating
7/12/2020Galmed PharmaceuticalsRoth CapitalReiterated Rating
5/22/2020Galmed PharmaceuticalsB. RileyDowngrade
5/15/2020Galmed PharmaceuticalsMaxim GroupInitiated Coverage
3/13/2020Galmed PharmaceuticalsStifel NicolausLower Price Target
2/4/2020Galmed PharmaceuticalsCraig HallumInitiated Coverage
7/22/2019Galmed PharmaceuticalsLaidlawInitiated Coverage
12/9/2020Aerpio PharmaceuticalsBTIG ResearchInitiated Coverage
3/18/2019Aerpio PharmaceuticalsGuggenheimDowngrade
3/18/2019Aerpio PharmaceuticalsNational SecuritiesDowngrade
2/18/2020NeuroBo PharmaceuticalsLADENBURG THALM/SH SHInitiated Coverage
2/19/2020Monopar TherapeuticsBrookline Capital ManagementInitiated Coverage
9/25/2020VaccinexOppenheimerLower Price Target
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.